
- /
- Supported exchanges
- / US
- / AZN.NASDAQ
AstraZeneca PLC ADR (AZN NASDAQ) stock market data APIs
AstraZeneca PLC ADR Financial Data Overview
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, Byetta, XIGDUO, Accolate, Accoleit, Vanticon, Beyfortus, Synagis, FluMist, tixagevimab and cilgavimab, and sipavibart. It also provides Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Bricanyl Turbuhaler, Rhinocort, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Breztri Aerosphere, Duaklir Genuair, Kavigale, Evusheld, Fluenz/FluMist, and Voydeya. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the United States, Europe, and Asia. It has a strategic agreement with Tempus to develop the largest multimodal foundation model in oncology. The company has a collaboration agreement with IonQ, Inc. for the development of quantum-accelerated computational chemistry workflow for healthcare, life sciences, and chemistry; and a strategic research collaboration with CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications. AstraZeneca PLC was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get AstraZeneca PLC ADR data using free add-ons & libraries
Get AstraZeneca PLC ADR Fundamental Data
AstraZeneca PLC ADR Fundamental data includes:
- Net Revenue: 54 982 M
- EBITDA: 18 277 M
- Earnings Per Share: 2
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-04-23
- EPS/Forecast: 1.1157
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
AstraZeneca PLC ADR News

Functional Dyspepsia Market Analysis and Forecast, 2025-2035, Competitive Analysis of AstraZeneca, P&G, Takeda, Prestige Consumer Healthcare, Kenvue Brands, Dr. Reddy's, Pfizer, ZERIA, Daewoong
Company Logo Functional dyspepsia, marked by untraceable upper abdominal discomfort, is seeing innovation through pharmacological treatments, lifestyle changes, and alternative therapies like herbal ...


Rapid Micro Biosystems (RPID) CEO sells $116976 in stock
Rapid Micro Biosystems , INC. (NASDAQ:RPID), a $147 million market cap company whose stock has surged over 270% year-to-date, reported that President and CEO Robert G. Spignesi, Jr., sold a total of 3...

AstraZeneca’s stock market exit would be devastating blow, warns ex-chancellor
Losing British drug giant AstraZeneca from the London Stock Exchange would be a “devastating blow”, Tory former chancellor Norman Lamont has said as he warned the Government against using pharma f...

Anal Cancer Market Research Report 2025-2035 with Competitive Profiles of Incyte, BioMimetix, Bristol Myers Squibb, and AstraZeneca
Company Logo Anal cancer is a rare yet increasing cancer linked primarily to high-risk HPV strains such as HPV-16 and HPV-18. Key risk factors include weakened immune systems, age over 50, and high-r...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.